NO982275L - Fremgangsmöter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF) - Google Patents

Fremgangsmöter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)

Info

Publication number
NO982275L
NO982275L NO982275A NO982275A NO982275L NO 982275 L NO982275 L NO 982275L NO 982275 A NO982275 A NO 982275A NO 982275 A NO982275 A NO 982275A NO 982275 L NO982275 L NO 982275L
Authority
NO
Norway
Prior art keywords
methods
treating
gdnf
photoreceptors
retinopathies
Prior art date
Application number
NO982275A
Other languages
English (en)
Norwegian (no)
Other versions
NO982275D0 (no
Inventor
Jean-Claude Marcel Louis
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO982275D0 publication Critical patent/NO982275D0/no
Publication of NO982275L publication Critical patent/NO982275L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Volatile Memory (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO982275A 1995-11-29 1998-05-19 Fremgangsmöter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF) NO982275L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/564,833 US5641750A (en) 1995-11-29 1995-11-29 Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
PCT/US1996/018806 WO1997019694A1 (en) 1995-11-29 1996-11-22 Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product

Publications (2)

Publication Number Publication Date
NO982275D0 NO982275D0 (no) 1998-05-19
NO982275L true NO982275L (no) 1998-07-29

Family

ID=24256084

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982275A NO982275L (no) 1995-11-29 1998-05-19 Fremgangsmöter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)

Country Status (20)

Country Link
US (2) US5641750A (de)
EP (1) EP0863766B1 (de)
JP (1) JP2000502057A (de)
KR (1) KR19990071540A (de)
CN (1) CN1203532A (de)
AT (1) ATE194773T1 (de)
AU (1) AU698062B2 (de)
BR (1) BR9611750A (de)
CZ (1) CZ154498A3 (de)
DE (1) DE69609422T2 (de)
DK (1) DK0863766T3 (de)
ES (1) ES2149511T3 (de)
GR (1) GR3034393T3 (de)
HU (1) HUP9802374A2 (de)
IL (1) IL124601A0 (de)
MX (1) MX9803993A (de)
NO (1) NO982275L (de)
PT (1) PT863766E (de)
SK (1) SK65998A3 (de)
WO (1) WO1997019694A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064870A1 (en) * 1993-03-03 2002-05-30 Pascale Briand Recombinant adenoviruses and use thereof in gene therapy for treating eye diseases
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
US8431119B2 (en) * 1993-10-04 2013-04-30 Aventis Pharma S.A. Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
FR2710846B1 (fr) 1993-10-04 1995-12-22 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives.
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
WO1998010785A1 (en) * 1996-09-13 1998-03-19 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
EP0937258A2 (de) * 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Humane durch zellstress regulierte mhc class i gene
NZ501423A (en) * 1997-04-17 2002-02-01 Univ Washington Receptors for TGF-beta-related neurotrophic factors and use for treating disease
US20030121064A1 (en) * 1997-06-11 2003-06-26 Ann Logan CNS neuroregenerative compositions and methods of use
WO1999015191A2 (en) * 1997-09-19 1999-04-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Cytokines having neurotrophic activity
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
FR2784898A1 (fr) * 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
US6906077B1 (en) * 1998-12-03 2005-06-14 Alcon Manufacturing, Ltd. Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
CA2361615A1 (en) * 1999-02-08 2000-08-10 Human Genome Sciences, Inc. The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
US20070071734A1 (en) * 1999-04-06 2007-03-29 Weng Tao ARPE-19 as platform cell line for encapsulated cell-based delivery
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
US7455855B2 (en) 2000-04-03 2008-11-25 Santen Pharmaceutical Co., Ltd. Delivering substance and drug delivery system using the same
US6864243B1 (en) 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
KR20020059609A (ko) 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 2
JP2004520009A (ja) * 2000-08-08 2004-07-08 エム.ジー.ヴィ.エス. リミテッド 核酸構築物、それにより形質転換された血管細胞、血管形成を誘発するためのそれを用いた医薬組成物および方法
CA2443918C (en) * 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 血管内皮増殖因子2
CN1318093C (zh) * 2001-09-28 2007-05-30 参天制药株式会社 含与聚乙二醇结合的药物的眼组织注射剂
US20030129164A1 (en) * 2001-12-03 2003-07-10 Flannery John G. Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
CA2469658A1 (en) * 2001-12-19 2003-07-03 Lijun Wang Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
WO2003061519A2 (en) * 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
EP1551956A4 (de) * 2002-07-12 2006-12-27 Univ Washington Verfahren und systeme zur verlängerten in-vitro-kultur neuronaler zellen
CA2689424A1 (en) * 2002-09-29 2004-04-08 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US20100158880A1 (en) * 2008-12-19 2010-06-24 Ethicon, Incorporated Regeneration and repair of neural tissue following injury
ES2569780T3 (es) * 2003-06-27 2016-05-12 DePuy Synthes Products, Inc. Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
GB0328021D0 (en) * 2003-12-03 2004-01-07 Inst Of Ophthalmology Method
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
WO2006083394A2 (en) * 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
WO2006101548A2 (en) * 2004-12-21 2006-09-28 Ethicon, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
ES2621847T3 (es) 2004-12-23 2017-07-05 DePuy Synthes Products, Inc. Células posparto derivadas de tejido de cordón umbilical, y métodos de elaboración y uso de las mismas
CA2589063C (en) 2004-12-23 2016-08-09 DePuy Synthes Products, Inc. Treatment of parkinson's disease and related disorders using postpartum derived cells
RU2284812C1 (ru) * 2005-02-15 2006-10-10 Уфимский научно-исследовательский институт глазных болезней Способ лечения пролиферативной витреоретинопатии
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US8409263B2 (en) * 2005-08-05 2013-04-02 Gholam A. Peyman Methods to regulate polarization of excitable cells
WO2007019427A2 (en) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
ITRM20050447A1 (it) * 2005-08-19 2007-02-20 Anabasis S R L Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
US9175261B2 (en) * 2005-12-16 2015-11-03 DePuy Synthes Products, Inc. Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
CN101437576A (zh) * 2005-12-28 2009-05-20 伊西康公司 使用产后衍生细胞治疗外周血管疾病
US20080145405A1 (en) * 2006-12-15 2008-06-19 Kunzler Jay F Drug delivery devices
MX2009011360A (es) 2007-04-20 2010-02-12 Acucela Inc Compuestos derivados de estirenilo para tratar enfermedades y trastornos oftalmicos.
NZ601866A (en) 2007-06-29 2013-12-20 Acucela Inc Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
EP2203186B1 (de) * 2007-10-05 2014-09-24 DePuy Synthes Products, LLC Reparatur und regeneration von nierengewebe mit zellen aus menschlicher nabelschnur
MX2010003667A (es) 2007-10-05 2010-09-28 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
WO2010071862A1 (en) * 2008-12-19 2010-06-24 Ethicon, Incorporated Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
US10557116B2 (en) 2008-12-19 2020-02-11 DePuy Synthes Products, Inc. Treatment of lung and pulmonary diseases and disorders
PL2411504T3 (pl) 2009-03-26 2017-10-31 Depuy Synthes Products Inc Komórki ludzkiej tkanki pępowinowej jako terapia choroby Alzheimera
KR101981450B1 (ko) 2011-12-23 2019-08-28 디퍼이 신테스 프로덕츠, 인코포레이티드 인간 제대 조직-유래된 세포의 검출
EP2804605A4 (de) 2012-01-20 2015-07-08 Acucela Inc Substituierte heterocyclische verbindungen zur behandlung von krankheiten
AU2014248878A1 (en) 2013-03-12 2015-09-24 Acucela Inc. Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
US10376562B2 (en) * 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
WO2021216378A1 (en) 2020-04-23 2021-10-28 The Schepens Eye Research Institute, Inc. Methods and materials for treatment of fibrosis
CN113759131B (zh) * 2021-09-28 2024-10-29 嘉兴蔚康科技有限公司 一种靶标蛋白组合在检测视网膜黄斑病变中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3995635A (en) * 1971-09-09 1976-12-07 Alza Corporation Ocular insert
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4217898A (en) * 1978-10-23 1980-08-19 Alza Corporation System with microporous reservoir having surface for diffusional delivery of agent
US4474452A (en) * 1981-05-13 1984-10-02 Pitney Bowes Inc. Safety device for cam yoke used in electrophotocopier reciprocating carriage
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4882150A (en) * 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP0401384B1 (de) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemisch modifizierte granulocytenkolonie erregender faktor
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
EP0676470A1 (de) * 1989-10-16 1995-10-11 Amgen Inc. Stammzellenfaktor
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1993006116A1 (en) * 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
DE69328730T2 (de) * 1992-02-14 2000-09-28 Regeneron Pharmaceuticals, Inc. Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
AU4114993A (en) * 1992-04-24 1993-11-29 Polymer Technology Group, Inc., The Biocompatible, therapeutic, implantable device
AU1443095A (en) * 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product

Also Published As

Publication number Publication date
DE69609422T2 (de) 2001-02-15
CN1203532A (zh) 1998-12-30
ATE194773T1 (de) 2000-08-15
SK65998A3 (en) 1999-09-10
US5736516A (en) 1998-04-07
WO1997019694A1 (en) 1997-06-05
ES2149511T3 (es) 2000-11-01
AU1059297A (en) 1997-06-19
US5641750A (en) 1997-06-24
BR9611750A (pt) 1999-04-06
MX9803993A (es) 1998-09-30
IL124601A0 (en) 1998-12-06
DK0863766T3 (da) 2000-10-23
DE69609422D1 (de) 2000-08-24
KR19990071540A (ko) 1999-09-27
EP0863766B1 (de) 2000-07-19
PT863766E (pt) 2000-11-30
NO982275D0 (no) 1998-05-19
HUP9802374A2 (hu) 1999-02-01
GR3034393T3 (en) 2000-12-29
EP0863766A1 (de) 1998-09-16
CZ154498A3 (cs) 1999-05-12
JP2000502057A (ja) 2000-02-22
AU698062B2 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
NO982275D0 (no) FremgangsmÕter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
NO982276L (no) Fremgangsmöte for behandling av retinal ganglioncelleskade under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
JP2021529528A5 (de)
ES8104412A1 (es) Procedimiento para la preparacion de un hidrolizado de pro- teinas purificado.
JPH03191791A (ja) 生物活性タンパク質の製造方法
WO2003047513A3 (en) Method for treating ocular hypertension
WO1993024529A1 (en) Retinal pigmented epithelium derived neurotrophic factor
HUP9900654A1 (hu) Körömnövekedést serkentő készítmény, eljárás előállítására és alkalmazása
DE122005000034I1 (de) Verfahren zur Reinigung von waessrigen Extrakten, die allergenische Proteine enthalten, so erhalteneExtrakte und ihre Verwendung.
DE69903612D1 (de) Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten
NO316926B1 (no) Fremgangsmate for fremstilling av et dimerisk biologisk aktivt TGF-<beta>-protein
AR022685A1 (es) Uso de estimulantes de factores neurotroficos para el tratamiento de enfermedades neurodegenerativas oftalmicas.
EP1050309A4 (de) Förderer der sekretion von neurotrophen faktoren
KR20010105931A (ko) 실크 펩타이드를 제조하는 방법
DK141172B (da) Fremgangsmåde til fremstilling af virusproteiner af influenzavirus.
HUP9802314A2 (hu) Zeaxantin tiszta 3R-3'R sztereoizomerje makuláris degeneráció emberben való kezelésére
WO2000053760A3 (en) Method of preventing the death of retinal neurons and treating ocular diseases
BR112022003508A2 (pt) Métodos para restaurar a função lisossômica de células epiteliais de pigmento da retina por ativação de tfeb
NO981687L (no) Lubeluzol N-oksid
SU1297845A1 (ru) Способ лечени миопии
BR112022012676A2 (pt) Composto químico e composição
DE50214894D1 (de) Verfahren zur herstellung von oxirancarbonsäuren und derivaten davon
SU1187829A1 (ru) Способ первичной обработки пуповины у новорожденного ребенка
JPH03249935A (ja) 乳化剤
de St Groth et al. Ovomucin: a substrate for the enzyme of influenza virus. II. Demonstration of its inhomogeneity